Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 10 of the 16 sources its claims cite were checked for support.
Abstract
Even though highly active anti-retroviral therapy is able to keep HIV-1 replication under control, the virus can lie in a dormant state within the host genome, known as a latent reservoir, and poses a threat to re-emerge at any time. However, novel technologies aimed at disrupting HIV-1 provirus may be capable of eradicating viral genomes from infected individuals. In this study, we showed the potential of the CRISPR/Cas9 system to edit the HIV-1 genome and block its expression. When LTR-targeting CRISPR/Cas9 components were transfected into HIV-1 LTR expression-dormant and -inducible T cells, a significant loss of LTR-driven expression was observed after stimulation. Sequence analysis confirmed that this CRISPR/Cas9 system efficiently cleaved and mutated LTR target sites. More importantly, this system was also able to remove internal viral genes from the host cell chromosome. Our results suggest that the CRISPR/Cas9 system may be a useful tool for curing HIV-1 infection.
Overview
CoChat Summary
TL;DR
The study shows that CRISPR/Cas9 targeting the HIV-1 LTR can disrupt proviral expression and excise integrated provirus in cell models. T5 gRNA targeting the TAR region was more effective than T6 targeting NF-κB, and repeated transfection improved suppression and excision.
Key findings
- In LTIG-transduced 293T cells, T5 gRNA reduced GFP-positive cells from 45.6% to 20.0% (p = 0.0003); triple transfection reduced GFP-positive cells from 40.8% to 2.1% (p = 0.0001).
- Sequence analysis found mutations in 18 of 22 HIV DNA clones, with 1–31-bp deletions from the putative cleavage site; two clones had deletion plus insertion mutations, consistent with NHEJ repair.
- In latent Jurkat clones c5 and c19, T5 reduced TNF-α-induced GFP-positive cells from 92.56% to 68.78% and from 98.48% to 66.95%, respectively; after three transfections in c19, reactivation fell from 97.8% to 35.5% (p = 0.00002).
- qPCR showed that on average 31.8% of provirus was excised after three transfections, and PCR detected a 1,067-bp footprint consistent with provirus excision leaving one LTR.
Methods
- Designed gRNA expression vectors targeting HIV-1 LTR: T5 against the TAR sequence in the R region and T6 against the NF-κB binding sequence in U3, co-transfected with human codon-optimized Cas9.
- Used HIV-1 provirus-integrated human cells: LTIG vector-transduced 293T and HeLa cells, plus Jurkat clones c5 and c19 that mimic HIV latency and were reactivated with TNF-α or 5-Aza-dC/TSA.
- Assessed GFP expression by flow cytometry, mutations by cloning and sequencing, proviral DNA amount by qPCR, and integration/excision by inverse PCR and flanking PCR; statistical analysis used Student’s t test.
Limitations
- The paper states that genome-editing and/or proviral excision efficiency should be quantified in HIV-infected primary cells, including latently infected CD4+ quiescent T cells.
- The paper states that an efficient delivery system must be developed and that possible off-target effects remain a concern for all genome-editing strategies.
- Evident from the text: most experiments use cell lines and engineered HIV vectors rather than primary patient cells; HeLa responses were modest, attributed to lower transfection efficiency and lower GFP expression; T6 was weaker because the 3′ NF-κB site may remain functional; and target-site mutations could allow some provirus to escape editing.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
10 Valid · 1 Not valid · 6 Not checked · 31 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While highly active anti-retroviral therapy (HARRT) has dramatically decreased mortality from HIV-1 infection, there is currently no effective strategy to target the latent form of HIV-1 proviruses 5 .”
What the sources say
- Partly supportedcites [5] Eisele, E. & Siliciano, R. F. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37, 377–388 (2012). sourceExperimental — accuracy not yet measured
The Introduction describes the latent reservoir as a major barrier to HIV-1 eradication. In “The latent reservoir in resting CD4+ T cells,” the paper says reactivation alone may not purge that reservoir, but it also reports that SAHA can perturb it in vivo. Thus, the paper supports the lack of an established strategy to eliminate latent infection, not the categorical claim that no strategy effectively targets it. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Fortunately, the CRISPR/Cas9 system has the advantage in size compared with TALENs 22 .”
What the sources say
- Partly supportedcites [22] Gaj, T., Gersbach, C. A. & Barbas, C. F. 3rd. ZFN, TALEN and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. (2013). sourceExperimental — accuracy not yet measured
The Future directions section says the large size of TALENs may limit delivery by size-restricted vectors. It does not compare TALEN size with CRISPR/Cas9 size, so it supports the TALEN size concern but not the claimed comparative advantage. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Triple TF resulted in a significant decrease in the mean percentage of GFP positive cells from 40.8% to 2.1% ( p = 0.0001) was observed.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this study, we successfully disrupted the expression of HIV-1 provirus utilizing the CRISPR/Cas9 system ( Fig. 1 ).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A similar reduction in GFP expression was observed in c5 and c19 cells transfected with the T5 CRISPR/Cas9 system after 5-Aza-dC/TSA treatment ( Fig. 3A and B ).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
23 more claims
Create a free account to see all 48 claims and every source verdict.
- Probably not a substantial claim. 8
- It may state two separate claims as one. 14
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ebina et al. (2013) used calcium phosphate transfection to deliver plasmid DNA encoding Cas9 and sgRNA into latent HIV-1-infected human 293 T cells.”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Ebina et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“various gene editing technologies have recently been shown to remove the proviral HIV-1 DNA from the host cell genome by targeting its highly conserved 5′ and 3′ long terminal repeats (LTRs)”
From RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection (2014) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the appropriate guide RNA, the Cas9 enzyme can recognize and cleave virtually any viral genome (29).”
From RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection (2014) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Off-target effects refer to the possibility that the CRISPR/Cas9 system may cut DNA at a non-specific location other than the target DNA, resulting in unwanted gene mutations or interference with normal gene function [10].”
From A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment (2024) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“However, this proof of concept is certainly applicable to any other cell type, including T-lymphoid cells (Fig. S6) (12,13), astrocytes, and neural stem cells”
From RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection (2014) · cites this paper as [12]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
Gaj, T., Gersbach, C. A., & Barbas, C. F. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.04.004 · Cited by 3,820
Gasiunas, G., Barrangou, R., Horvath, P., & Siksnys, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208507109 · Cited by 2,769
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease
Cho, S. W., Kim, S., Kim, J. M., & Kim, J.-S. (2013) · Nature Biotechnology · doi:10.1038/nbt.2507 · Cited by 1,863
RNA-guided genetic silencing systems in bacteria and archaea
Wiedenheft, B., Sternberg, S. H., & Doudna, J. A. (2012) · Nature · doi:10.1038/nature10886 · Cited by 1,851
Highly efficient endogenous human gene correction using designed zinc-finger nucleases
Urnov, F. D., Miller, J. C., Lee, Y.-L., Beausejour, C. M., Rock, J. M., Augustus, S., Jamieson, A. C., Porteus, M. H., Gregory, P. D., & Holmes, M. C. (2005) · Nature · doi:10.1038/nature03556 · Cited by 1,641
Makarova, K. S., Grishin, N. V., Shabalina, S. A., Wolf, Y. I., & Koonin, E. V. (2006) · Biology Direct · doi:10.1186/1745-6150-1-7 · Cited by 1,199
Development of a self-inactivating lentivirus vector
Miyoshi, H., Blömer, U., Takahashi, M., Gage, F. H., & Verma, I. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.8150-8157.1998 · Cited by 1,196
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro
Jordan, A., Bisgrove, D., & Verdin, E. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg188 · Cited by 914
Cited by
Items 201–300 of 562
CRISPR/Cas9 Genome Editing to Disable the Latent HIV-1 Provirus
Panfil, A. R., London, J. A., Green, P. L., & Yoder, K. E. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03107 · Cited by 36
“One exciting concept targeted the long terminal repeats (LTRs) present at each end of the provirus (Ebina et al., 2013; Dampier et al., 2014; Hu et al., 2014; Kaminski et al., 2016a,b; Yin C. et al., 2016; Yin C. et al., 2017; Bella et al., 2018).”
BackgroundTremblay, J. P. (2015) · médecine/sciences · doi:10.1051/medsci/20153111016 · Cited by 48
CRISPR/Cas9—Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development
Okoli, A. S., Okeke, M. I., Tryland, M., & Moens, U. L. (2018) · Viruses · doi:10.3390/v10010050 · Cited by 40
Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics
Dampier, W., Sullivan, N. T., Mell, J. C., Pirrone, V., Ehrlich, G. D., Chung, C.-H., Allen, A. G., Desimone, M., Zhong, W., Kercher, K., et al. (2018) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2017.0274 · Cited by 39
Targeting the latent reservoir to achieve functional HIV cure
Cary, D. C., & Peterlin, B. M. (2016) · F1000Research · doi:10.12688/f1000research.8109.1 · Cited by 32
Cornu, T. I., Mussolino, C., Müller, M. C., Wehr, C., Kern, W. V., & Cathomen, T. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.159 · Cited by 36
Sonti, S., Sharma, A. L., & Tyagi, M. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198523 · Cited by 34
“It was recently reported that the latency reversal activity of the HDAC inhibitor, Vorinostat (SAHA) was augmented following ACSS2 induction and histone crotonylation (H3K4Cr) indicating that crotonylation of histone tails at the HIV-1 LTR plays a major role in regulating HIV-1 latency (Jiang et al., 2018).”
BackgroundInfluentialQu, D., Li, C., Sang, F., Li, Q., Jiang, Z., Xu, L., Guo, H., Zhang, C., & Wang, J. (2016) · Scientific Reports · doi:10.1038/srep34532 · Cited by 38
Trevisan, M., Sinigaglia, A., Desole, G., Berto, A., Pacenti, M., Palù, G., & Barzon, L. (2015) · Viruses · doi:10.3390/v7072800 · Cited by 28
“In the first anti-HIV approach that exploits iPSCs, gene-editing tools were used to excide the integrated HIV-1 provirus from the host cell genome [98–100] and to directly target and disrupt the reverse-transcribed HIV genome within host cells [101].”
Ding, R., Long, J., Yuan, M., Jin, Y., Yang, H., Chen, M., Chen, S., & Duan, G. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.639108 · Cited by 35
Modulation of Gene Expression by Polymer Nanocapsule Delivery of DNA Cassettes Encoding Small RNAs
Yan, M., Wen, J., Liang, M., Lu, Y., Kamata, M., & Chen, I. S. Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127986 · Cited by 29
“However, effective delivery of CRISPR/Cas9 reagents into target cells is the key limitation for therapeutic applications[16,27].”
BackgroundTherapy of HIV Infection: Current Approaches and Prospects
Prokofjeva, M. M., Kochetkov, S. N., & Prassolov, V. (2016) · Acta Naturae · doi:10.32607/20758251-2016-8-4-23-32 · Cited by 34
Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview
Boomgarden, A. C., & Upadhyay, C. (2025) · Vaccines · doi:10.3390/vaccines13020148 · Cited by 41
“Both Ebina et al and Hu et al demonstrated that the CRISPR/Cas9-based targeting of HIV-1 long terminal repeat (LTR) sequences in infected T cells could effectively block viral gene expression and replication [222,223].”
Weber, N. D., Aubert, M., Dang, C. H., Stone, D., & Jerome, K. R. (2014) · Virology · doi:10.1016/j.virol.2013.12.037 · Cited by 30
“Comparable outcomes have been achieved by targeting the HIV LTR with the CRISPR/Cas9 system in infected cell lines [17].”
BackgroundCompounds producing an effective combinatorial regimen for disruption of HIV‐1 latency
Hashemi, P., Barreto, K., Bernhard, W., Lomness, A., Honson, N. S., Pfeifer, T. A., Harrigan, P. R., & Sadowski, I. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201708193 · Cited by 32
“In particular, the gene-editing technology CRISPR/Cas9, which is aimed at disrupting genes associated with HIV-1, has recently attracted considerable attention in the field (Ebina et al, 2013; Hu et al, 2014; Zhu et al, 2015; Kaminski et al, 2016).”
BackgroundImprovement of baculovirus as protein expression vector and as biopesticide by CRISPR/Cas9 editing
Pazmiño‐Ibarra, V., Mengual‐Martí, A., Targovnik, A. M., & Herrero, S. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.27139 · Cited by 30
“Gene edition using CRISPR/Cas9 system has been recently reported in other viral genomes with biomedical implications such adenovirus (ADV) (22), type I herpes simplex virus (HSV-1) (15, 23), HIV-1 provirus (24), Epstein-Barr virus (25) and Human Cytomegalovirus (26).”
BackgroundSullivan, N. T., Dampier, W., Chung, C.-H., Allen, A. G., Atkins, A., Pirrone, V., Homan, G., Passic, S. R., Williams, J. W., Zhong, W., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-52353-9 · Cited by 34
Targeted Chromatinization and Repression of HIV-1 Provirus Transcription with Repurposed CRISPR/Cas9
Olson, A., Basukala, B., Lee, S., Gagné, M., Wong, W. W., & Henderson, A. J. (2020) · Viruses · doi:10.3390/v12101154 · Cited by 30
Lai, M., Maori, E., Quaranta, P., Matteoli, G., Maggi, F., Sgarbanti, M., Crucitta, S., Pacini, S., Turriziani, O., Antonelli, G., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01358-21 · Cited by 28
“genome (provirus) from the host cell genome (3) and has proven effective in eliminating,”
BackgroundInfluentialDeciphering DNA Methylation in HIV Infection
Arumugam, T., Ramphal, U., Adimulam, T., Chinniah, R., & Ramsuran, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.795121 · Cited by 36
CRISPR-Cas systems: role in cellular processes beyond adaptive immunity
Devi, V., Harjai, K., & Chhibber, S. (2022) · Folia Microbiologica · doi:10.1007/s12223-022-00993-2 · Cited by 34
“Impeccable finding that CRISPR-Cas system can be used for genome editing technologies has opened up the prospects for the use of this system for therapeutic purposes especially for the treatment of cardiovascular diseases, genetic disorders, autoimmune, inflammatory, and immunological disorders, bacterial and viral di…”
BackgroundHuang, Z., & Nair, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-06269-x · Cited by 30
Humanized Mice for the Evaluation of Novel HIV-1 Therapies
Abeynaike, S. A., & Paust, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636775 · Cited by 32
Construction of Baculovirus-Inducible CRISPR/Cas9 Antiviral System Targeting BmNPV in Bombyx mori
Liu, Y., Chen, D., Zhang, X., Chen, S., Yang, D., Tang, L., Xu, Y., Wang, Y., Luo, X., Wang, M., et al. (2021) · Viruses · doi:10.3390/v14010059 · Cited by 27
Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense
Price, A. A., Grakoui, A., & Weiss, D. S. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.01.005 · Cited by 28
Dong, Z., Huang, L., Dong, F., et al. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9295-8 · Cited by 27
Development of Anti-HIV Therapeutics: From Conventional Drug Discovery to Cutting-Edge Technology
Sun, Y., & Wang, L. (2024) · Pharmaceuticals · doi:10.3390/ph17070887 · Cited by 30
“…designed gRNA to target HIV-1 long terminal repeat (LTR) in specific locations of the TAR sequence of the R region and NF-κ B binding sequence in the U3 region, respectively, and this LTR-targeted CRISPR/Cas9 system can disrupt HIV-1 provirus and active the provirus from the cellular genome [80].”
BackgroundKumari, R., Saha, T., Kumar, P., & Singh, A. K. (2024) · Physiology and Molecular Biology of Plants · doi:10.1007/s12298-024-01486-x · Cited by 33
Therapeutic applications of CRISPR RNA-guided genome editing
Koo, T., & Kim, J. (2016) · Briefings in Functional Genomics · doi:10.1093/bfgp/elw032 · Cited by 26
Llewellyn, G. N., Seclén, E., Wietgrefe, S. W., Liu, S., Chateau, M., Pei, H., Perkey, K., Marsden, M. D., Hinkley, S. J., Paschon, D. E., et al. (2019) · Journal of Virology · doi:10.1128/jvi.02086-18 · Cited by 32
A cure for HIV: is it in sight?
Pace, M. J., & Frater, J. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.910112 · Cited by 35
“Initial in vitro studies using a HIV targeting CRISPR/Cas9 system showed that this approach could successfully cleave and mutate HIV in vitro [14].”
BackgroundAdvances in therapeutic application of CRISPR-Cas9
Sun, J., Wang, J., Zheng, D., & Hu, X. (2019) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz031 · Cited by 26
The potential of HBV cure: an overview of CRISPR-mediated HBV gene disruption
Yao, Z. Q., Schank, M., Zhao, J., Gazzar, M. E., Wang, L., Zhang, Y., Hill, A. C., Banik, P., Pyburn, J. S., & Moorman, J. P. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1467449 · Cited by 32
Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape
White, M. K., Hu, W., & Khalili, K. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005953 · Cited by 24
Ophinni, Y., Miki, S., Hayashi, Y., & Kameoka, M. (2020) · Viruses · doi:10.3390/v12111223 · Cited by 29
SMAC Mimetics as Therapeutic Agents in HIV Infection
Molyer, B., Kumar, A., & Angel, J. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.780400 · Cited by 25
“Some of these focus on activating the latent reservoir followed by immune mediated elimination of the virus (shock and kill) (18), gene editing to excise/mutate the provirus (19) and using transcriptional gene silencing to preserve the mechanisms that lead to the maintenance of HIV latency to functionally prevent any…”
BackgroundUpdates on CRISPR-based gene editing in HIV-1/AIDS therapy
Zhang, Z., Hou, W., & Chen, S. (2022) · Virologica Sinica · doi:10.1016/j.virs.2022.01.017 · Cited by 35
“In addition to inhibiting HIV-1 proviral DNA transcription and viral replication, CRISPR/SpCas9 can eliminate integrated viral genes in the host chromosome (Ebina et al., 2013).”
BackgroundTripathi, S., Khatri, P., Fatima, Z., Pandey, R. P., & Hameed, S. (2022) · Pathogens · doi:10.3390/pathogens12010056 · Cited by 37
“Numerous research studies using CRISPR/Cas9 technology as a means for treating HIV/AIDS have been created quickly since the first two CRISPR/Cas9-based applications in the prevention of HIV-1 were reported by Cho and Ebina, respectively, in 2013 [12,150].”
MethodCRISPR-Based Therapies: Revolutionizing Drug Development and Precision Medicine
Chanchal, D. K., Chaudhary, J. S., Kumar, P., Agnihotri, N., & Porwal, P. (2024) · Current Gene Therapy · doi:10.2174/0115665232275754231204072320 · Cited by 25
CRISPR/Cas9-mediated multiple single guide RNAs potently abrogate pseudorabies virus replication
Tang, Y.-D., Liu, J.-T., Wang, T.-Y., Sun, M.-X., Tian, Z.-J., & Cai, X.-H. (2017) · Archives of Virology · doi:10.1007/s00705-017-3553-4 · Cited by 22
“More importantly, it has been reported that CRISPR/Cas9 has been used to successfully eradiate integrated proviral HIV-1 DNA as well as latent infection with several human herpesviruses [5, 8, 9, 23].”
BackgroundStrategies to target HIV-1 in the central nervous system
Gray, L. R., Brew, B. J., & Churchill, M. J. (2016) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000278 · Cited by 29
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Naeem, M., Alkhodairy, H. F., Ashraf, I., & Khalil, A. B. (2022) · Arabian Journal for Science and Engineering · doi:10.1007/s13369-022-07266-7 · Cited by 29
Attacking HIV-1 RNA versus DNA by sequence-specific approaches: RNAi versus CRISPR-Cas
Herrera-Carrillo, E., & Berkhout, B. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160060 · Cited by 25
Novel AIDS therapies based on gene editing
Khalili, K., White, M. K., & Jacobson, J. M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2479-z · Cited by 25
CRISPR editing in biological and biomedical investigation
Huang, J., Wang, Y., & Zhao, J. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26141 · Cited by 27
“Ebina et al. (2013) firstly showed that HIV-1 LTR sequence can be mutated via CRISPR/Cas9 in vitro, and resulted in removal of the integrated proviral DNA from the part of the host cells and a significant drop in virus expression.”
BackgroundCRISPR/Cas9 Genome Editing Using Gold‐Nanoparticle‐Mediated Laserporation
Bošnjak, B., Permanyer, M., Sethi, M. K., Galla, M., Maetzig, T., Heinemann, D., Willenzon, S., Förster, R., Heisterkamp, A., & Kalies, S. (2018) · Advanced Biosystems · doi:10.1002/adbi.201700184 · Cited by 26
Cell and gene therapy strategies to eradicate HIV reservoirs
Spragg, C. J., Feelixge, H. S. D. S., & Jerome, K. R. (2016) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000284 · Cited by 25
Zhou, W., Yang, J., Zhang, Y., Hu, X., & Wang, W. (2022) · MedComm · doi:10.1002/mco2.155 · Cited by 31
A comprehensive overview of CRISPR/Cas 9 technology and application thereof in drug discovery
Khurana, A., Sayed, N., Singh, V., Khurana, I., Allawadhi, P., Rawat, P. S., Navik, U., Pasumarthi, S. K., Bharani, K. K., & Weiskirchen, R. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30329 · Cited by 29
“To eliminate these latent reservoirs, shock and kill therapy is used in the treatment which is a nontargeted approach.(105) Moreover, the dynamic and heterogeneous character of the drugs could lead to abridged safety and efficacy of the strategy.”
BackgroundDance, A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1503840112 · Cited by 23
CRISPR Editing Technology in Biological and Biomedical Investigation
White, M. K., Kaminski, R., Young, W., Roehm, P. C., & Khalili, K. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26099 · Cited by 27
“…facilitates the excision of HIV proviral DNA segments in several different cell types including CD4þ T-cells and by targeting the flanking HIV-1 LTR sequences, complete excision of proviral DNA can be effected [Ebina et al., 2013; Hu et al., 2014; Kaminski et al., 2016b; Yin et al., 2016].”
BackgroundReprogramming MHC specificity by CRISPR-Cas9-assisted cassette exchange
Kelton, W., Waindok, A. C., Pesch, T., Pogson, M., Ford, K., Parola, C., & Reddy, S. T. (2017) · Scientific Reports · doi:10.1038/srep45775 · Cited by 21
Nasrallah, A., Sulpice, E., Kobaisi, F., Gidrol, X., & Rachidi, W. (2022) · Cells · doi:10.3390/cells11223615 · Cited by 27
Mechanisms of Immune Evasion in HIV-1: The Role of Virus-Host Protein Interactions
Mouzakis, A., Petrakis, V., Tryfonopoulou, E., Panopoulou, M. I., Panagopoulos, P., & Chlichlia, K. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47050367 · Cited by 26
“These interventions have led to the inhibition of proviral transcription, suppression of viral replication, and, in some cases, excision of integrated viral DNA from host cell chromosomes [123–127].”
Genome editing-based HIV therapies
Gu, W.-G. (2015) · Trends in biotechnology · doi:10.1016/j.tibtech.2014.12.006 · Cited by 23
Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions
Sebastian, N. T., & Collins, K. L. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.956094 · Cited by 20
Harnessing CRISPR/Cas 9 System for manipulation of DNA virus genome
Ebrahimi, S., Teimoori, A., Khanbabaei, H., & Tabasi, M. (2018) · Reviews in Medical Virology · doi:10.1002/rmv.2009 · Cited by 20
“They designed sgRNAs for LTR region, resulting in a remarkable removal and eradication of proviral genome integrated in host genome.(115) Similarly, several studies demonstrated excision and elimination of integrated HIV genome by the CRISPR/ Cas9 system in different HIV‐1 latent reservoir cells.”
BackgroundCRISPR/Cas Genome Editing in Filamentous Fungi
Рожкова, А. М., & Kislitsin, V. Y. (2021) · Biochemistry (Moscow) · doi:10.1134/s0006297921140091 · Cited by 26
Application of gene-editing technologies to HIV-1
Drake, M. J., & Bates, P. F. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000139 · Cited by 21
Editing out HIV: application of gene editing technology to achieve functional cure
Xun, J., Zhang, X., Guo, S., Lu, H., & Chen, J. (2021) · Retrovirology · doi:10.1186/s12977-021-00581-1 · Cited by 24
CRISPR/Cas9 system and its applications in human hematopoietic cells
Hu, X. (2016) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2016.09.003 · Cited by 22
Gene editing in dermatology: Harnessing CRISPR for the treatment of cutaneous disease
Baker, C. M., & Hayden, M. S. (2020) · F1000Research · doi:10.12688/f1000research.23185.1 · Cited by 29
Experimental Approaches for Eliminating Latent HIV
Marsden, M. D., & Zack, J. A. (2015) · Forum on Immunopathological Diseases and Therapeutics · doi:10.1615/forumimmundisther.2016015242 · Cited by 22
Gene therapy of hematological disorders: current challenges
Al-Saif, A. M. (2019) · Gene Therapy · doi:10.1038/s41434-019-0093-4 · Cited by 21
CRISPR Genome Editing Applied to the Pathogenic Retrovirus HTLV-1
Panfil, A. R., Green, P. L., & Yoder, K. E. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.580371 · Cited by 17
“To date, CRISPR editing of retroviral proviruses has been largely limited to HIV-1 (Ebina et al., 2013; Rihn et al., 2013; Hu et al., 2014; Liao et al., 2015; Rihn et al., 2015; Zhu et al., 2015; Kaminski et al., 2016; Yoder and Bundschuh, 2016; Yin et al., 2017; Lebbink et al., 2017; Ophinni et…”
BackgroundStem Cell Therapy and Its Significance in HIV Infection
Khalid, K., Padda, J., Fernando, R. W., Mehta, K. A., Almanie, A. H., Hennawi, H. A., Padda, S., Cooper, A. C., & Jean-Charles, G. (2021) · Cureus · doi:10.7759/cureus.17507 · Cited by 22
CRISPR‐Cas9 delivery strategies and applications: Review and update
Severi, A. A., & Akbari, B. (2024) · genesis · doi:10.1002/dvg.23598 · Cited by 27
“HIV is a retrovirus that weakens the body's immune system by the LTR in HIV-1 provirus DNA (Ebina et al., 2013; Janik et al., 2020; Liu & Eiden, 2011; Sharma et al., 2021).”
BackgroundNeuroprotective therapies in glaucoma: II. Genetic nanotechnology tools
Nafissi, N., & Földvári, M. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00355 · Cited by 19
“…into the infected host cell genome and deactivating the viral genes necessary for pathogenesis or reproduction, reassembly and release of new viruses (Ebina et al., 2013; Hu et al., 2014); and (F) facilitate precise ex vivo remodeling of stem/progenitor cells (Doudna and Charpentier, 2014).”
How to Define the Latent Reservoir: Tools of the Trade
Barton, K., & Palmer, S. (2016) · Current HIV/AIDS Reports · doi:10.1007/s11904-016-0304-1 · Cited by 18
Roointan, A., & Morowvat, M. H. (2016) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2016.1270095 · Cited by 18
The state of gene therapy research in Africa, its significance and implications for the future
Arbuthnot, P. B., Maepa, M. B., Ely, A., & Pepper, M. S. (2017) · Gene Therapy · doi:10.1038/gt.2017.57 · Cited by 21
“32, 33 Although inactivation of the provirus has been observed, delivery of gene editors to all reservoirs of latently infected cells remains challenging.”
BackgroundZhao, N., Wang, G., Das, A. T., & Berkhout, B. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01486-17 · Cited by 23
Viral Vectors, Engineered Cells and the CRISPR Revolution
DiCarlo, J. E., Deeconda, A., & Tsang, S. H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63904-8_1 · Cited by 21
CRISPR/Cas9 therapeutics for liver diseases
Aravalli, R. N., & Steer, C. J. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26627 · Cited by 19
Chung, C.-H., Allen, A. G., Atkins, A., Sullivan, N. T., Homan, G., Costello, R., Madrid, R., Nonnemacher, M. R., Dampier, W., & Wigdahl, B. L. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.07.016 · Cited by 24
“19 20 – 24 There are identical copies of the LTR on each end of the integrated provirus.”
Rapid, precise quantification of large DNA excisions and inversions by ddPCR
Watry, H. L., Feliciano, C. M., Gjoni, K., Takahashi, G., Miyaoka, Y., Conklin, B. R., & Judge, L. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-71742-z · Cited by 18
Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic
Kennedy, E. M., Kornepati, A. V. R., Mefferd, A. L., Marshall, J. B., Tsai, K., Bogerd, H. P., & Cullen, B. R. (2015) · Methods · doi:10.1016/j.ymeth.2015.08.012 · Cited by 19
Efficient inhibition of duck hepatitis B virus DNA by the CRISPR/Cas9 system
Zheng, Q., Bai, L., Zheng, S., Liu, M., Zhang, J., Wang, T., Xu, Z., Chen, Y., Li, J., & Duan, Z. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7518 · Cited by 19
“Only sgRNAs targeting specific genes are required for highly efficient gene modification using the CRISPR/Cas9 system (26,27).”
MethodGenome editing technologies to fight infectious diseases
Trevisan, M., Palù, G., & Barzon, L. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1400379 · Cited by 18
“were the first to demonstrate the potential of the CRISPRCas9 system to edit the HIV-1 genome by blocking its expression via targeting the LTR promoter region and by showing disruption and excision of the latent provirus from human cells [26].”
BackgroundCRISPR/Cas9 and Genome Editing for Viral Disease—Is Resistance Futile?
Feelixge, H. S. D. S., Stone, D., Roychoudhury, P., Aubert, M., & Jerome, K. R. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00273 · Cited by 23
Schwarzer, R., Gramatica, A., & Greene, W. C. (2020) · Viruses · doi:10.3390/v12020188 · Cited by 25
Maslennikova, A., & Mazurov, D. V. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.880030 · Cited by 27
“Many early studies showed that CRISPR/Cas9 can effectively inactivate HIV-1 proviruses by targeting different regions of the viral genome (Ebina et al., 2013; Hu et al., 2014; Liao et al., 2015; Zhu et al., 2015), leading to much excitement in the field.”
BackgroundRodrigues, J. L., Ferreira, D., & Rodrigues, L. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-08-100741-9.00016-4 · Cited by 19
CRISPR/Cas9 in epigenetics studies of health and disease
Sar, P., & Dalai, S. K. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.022 · Cited by 21
Advances in CRISPR-based gene editing technology and its application in nucleic acid detection
Chen, L., LI, J., Chen, J., Duan, L., Hu, Z., Li, K., Liao, D., & HE, N. (2024) · Biocell · doi:10.32604/biocell.2024.056698 · Cited by 17
Far, B. F., Akbari, M., Habibi, M. A., Katavand, M., & Nasseri, S. (2025) · Cell Proliferation · doi:10.1111/cpr.70099 · Cited by 28
HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing
Lyons, D. E., Kumar, P., Roan, N. R., Defechereux, P. A., Feschotte, C., Lange, U. C., Murthy, N., Sameshima, P., Verdin, E. M., Ake, J. A., et al. (2023) · Viruses · doi:10.3390/v15112171 · Cited by 19
HIV vaccination: Navigating the path to a transformative breakthrough—A review of current evidence
Scott, G. Y., & Worku, D. A. (2024) · Health Science Reports · doi:10.1002/hsr2.70089 · Cited by 19
“42,43 mRNA, which is subsequently spliced and transported out of the nucleus into the cytoplasm, is created by the transcription of the provirus by the host cell RNA polymerase II enzyme.”
BackgroundWen, Y., Liao, G., Pritchard, T., Zhao, T., Connelly, J. P., Pruett‐Miller, S. M., Blanc, V., Davidson, N. O., & Madison, B. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.777722 · Cited by 19
Genome-Edited T Cell Therapies
Delhove, J. M. K. M., & Qasim, W. (2017) · Current Stem Cell Reports · doi:10.1007/s40778-017-0077-5 · Cited by 19
Gene editing in T cell therapy
Zhang, Y., Mu, W., & Wang, H. (2017) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2017.09.002 · Cited by 18
Developmental progress of CRISPR/Cas9 and its therapeutic applications for HIV‐1 infection
Deng, Q., Chen, Z., Shi, L., & Lin, H. (2018) · Reviews in Medical Virology · doi:10.1002/rmv.1998 · Cited by 18
Genetic Strategies for HIV Treatment and Prevention
Falkenhagen, A., & Joshi, S. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.09.018 · Cited by 17
“Similarly, the CRISPR/Cas9 system has been used to excise HIV provirus DNA from infected cells.(48) However, HIV was shown to rapidly develop resistance to excision by Cas9.”
MethodThe Origins and Genetic Diversity of HIV-1: Evolutionary Insights and Global Health Perspectives
Alexiev, I., & Dimitrova, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210909 · Cited by 25
“Cu-rative strategies, including CRISPR/Cas9, remain complex due to latent viral reservoirs unaffected by standard ART [43], though preclinical studies suggest potential for excising of latent genomes [44].”
Pitfalls of Antiretroviral Therapy: Current Status and Long-Term CNS Toxicity
Rudd, H., & Toborek, M. J. (2022) · Biomolecules · doi:10.3390/biom12070894 · Cited by 19
“The gene expression of HIV is controlled by promoter and enhancer sequences where transcription factors, including NF-κB, can bind, promoting RNA polymerase II activity, ultimately resulting in increased virus-specific protein levels [15].”
BackgroundHIV cure strategies: which ones are appropriate for Africa?
Abana, C. Z.-Y., Lamptey, H., Bonney, E. Y., & Kyei, G. B. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04421-z · Cited by 17
“first applied this technology to HIV in cell culture to target the integrated provirus [156].”
MethodThe Dawn of In Vivo Gene Editing Era: A Revolution in the Making
Niazi, S. K. (2023) · Biologics · doi:10.3390/biologics3040014 · Cited by 23
Zhou, L., & Simonian, A. L. (2024) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-081723-013033 · Cited by 19
Zinc finger nuclease: a new approach for excising HIV-1 proviral DNA from infected human T cells
Qu, X., Wang, P., Ding, D., Wang, X., Zhang, G., Zhou, X., Liu, L., Zhu, X., Zeng, H., & Zhu, H. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3456-3 · Cited by 20
“nucleases, homing endonucleases and clustered regularly interspaced short palindromic repeats (CRISPR)/cas9 [10– 12].”
Background
Metadata
- Authors
- Ebina, H., Misawa, N., Kanemura, Y., & Koyanagi, Y.
- Affiliations
- Kyoto University (JP)
- Corresponding author
- Ebina, Hirotaka
- Venue
- Scientific Reports
- Published
- 2013-08-26
- Volume
- 3
- Issue
- 1
- Pages
- 2510-2510
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC3752613
- OpenAlex
- W1966452674
- Cited by
- 565
- References
- 28
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 39 · 2023: 28 · 2022: 50 · 2021: 52 · 2020: 51 · 2019: 35 · 2018: 46 · 2017: 58 · 2016: 73 · 2015: 61 · 2014: 36 · 2013: 3
- FWCI
- 25.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/3.0/ (tdm)
- creativecommons.org/licenses/by/3.0/ (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology (24115008)
- Japan Society for the Promotion of Science (24790438, 24390112)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- CRISPR/Cas9, HIV-1 provirus, latent HIV-1 reservoir, HIV-1 latency, HIV-1 cure, genome editing, T cells, HIV-1 reactivation
- MeSH terms
- HeLa Cells, Humans, HIV-1, HIV Long Terminal Repeat, Virus Latency, Gene Silencing, HEK293 Cells, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.